NCT05481177 (COVIVA) is a Phase 4 clinical trial of Ivabradine in Long Haul COVID, sponsored by Uniformed Services University of the Health Sciences.

Who is sponsoring NCT05481177?

NCT05481177 is sponsored by Uniformed Services University of the Health Sciences.

What drugs are being tested in NCT05481177?

Interventions in NCT05481177: Ivabradine.

What condition does NCT05481177 study?

NCT05481177 studies Long Haul COVID, Postural Orthostatic Tachycardia Syndrome.

Is NCT05481177 still recruiting?

NCT05481177 is currently status unknown. Last updated 29 November 2023.

Last reviewed 2023-11-29 · How we verify

NCT05481177: COVIVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort

Status unknown Phase 4 Last updated 29 November 2023

What this trial tests

Phase 4 trial testing Ivabradine in Long Haul COVID in 250 participants. Status unknown.

Timeline

14 June 2023

Primary endpoint
1 September 2024

1 September 2024

Quick facts

Lead sponsor	Uniformed Services University of the Health Sciences
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	250
Start date	14 June 2023
Primary completion	1 September 2024
Estimated completion	1 September 2024
Sites	1 location across United States

Drugs / interventions tested

Ivabradine (IVABRADINE) — full drug profile →

Conditions studied

Long Haul COVID — all drugs for Long Haul COVID →
Postural Orthostatic Tachycardia Syndrome — all drugs for Postural Orthostatic Tachycardia Syndrome →

Sponsor

Uniformed Services University of the Health Sciences

Who can join

Adults 18 to 80, any sex, with Long Haul COVID or Postural Orthostatic Tachycardia Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is three-fold. The primary aim is to identify the proportion of Long-Haul COVID (LHC) and non-LHC volunteers with relevant symptoms actually have postural orthostatic tachycardia syndrome (POTS). The second is to determine benefit of ivabradine treatment. Ivabradine is a drug approved to treat tachycardia in persons with heart failure. The third is to characterize risk factors and outcomes among volunteers with and without LHC. This will include comparison with COVID-19-positive individuals who did not develop long-COVID symptoms. The study will improve basic and applied knowledge of LHC and its associated cardiovascular and autonomic consequences. Cellular and molecular characterization of LHC and non-LHC participants will be performed with a nested clinical trial for Ivabradine responsiveness on reduction of tachycardia. It is hoped that a greater understanding of LHC, and related autonomic dysfunction in particular will help to identify treatment paradigms and therapeutic targets for improving recovery and enhancing health for those affected.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID.
Li J, Zhou Y, Ma J, Zhang Q, et al · · 2023 · cited 91× · PMID 37907497 · DOI 10.1038/s41392-023-01640-z
Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative.
Bonilla H, Peluso MJ, Rodgers K, Aberg JA, et al · · 2023 · cited 72× · PMID 36969241 · DOI 10.3389/fimmu.2023.1129459
Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies.
Zadeh FH, Wilson DR, Agrawal DK. · · 2023 · cited 36× · PMID 37388279 · DOI 10.26502/ami.93650103
Cardiovascular disease and covid-19: A systematic review.
Krishna BA, Metaxaki M, Sithole N, Landín P, et al · · 2024 · cited 17× · PMID 39189008 · DOI 10.1016/j.ijcha.2024.101482
Postural Orthostatic Tachycardia Syndrome in COVID-19: A Contemporary Review of Mechanisms, Clinical Course and Management.
Narasimhan B, Calambur A, Moras E, Wu L, et al · · 2023 · cited 14× · PMID 37204997 · DOI 10.2147/vhrm.s380270
The current landscape of long COVID clinical trials: NIH's RECOVER to Stanford Medicine's STOP-PASC initiative.
Chakraborty C, Bhattacharya M. · · 2023 · cited 7× · PMID 37680987 · DOI 10.1016/j.omtn.2023.08.016
Evidence for targeting autonomic dysfunction in systemic sclerosis: A scoping review.
Cuevas S, Mayer E, Hughes M, Adler BL, et al · · 2025 · cited 6× · PMID 39790996 · DOI 10.1177/23971983241308050
Comparative cohort study of post-acute COVID-19 infection with a nested, randomized controlled trial of ivabradine for those with postural orthostatic tachycardia syndrome (the COVIVA study).
Saunders D, Arnold TB, Lavender JM, Bi D, et al · · 2025 · cited 2× · PMID 40692561 · DOI 10.3389/fneur.2025.1550636

Verify or expand the search:

Other trials of Ivabradine

Trials testing the same drug.

NCT07268170 — Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease · Phase 2, PHASE3 · enrolling by invitation
NCT06312891 — Value of Heart Rate Lowering Therapy in Acute Myocarditis · unknown
NCT06305806 — RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) · Phase 2 · completed
NCT06670690 — Comparison Between Atenolol,Propnalol and Ivabradine · NA · completed
NCT05882708 — Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis · Phase 4 · unknown

Other Uniformed Services University of the Health Sciences trials

Trials by the same sponsor.

NCT07404787 — Evaluation of a Telehealth Case Management Intervention to Prevent Suicide Among Soldiers Discharged From Psychiatric Ho · NA · recruiting
NCT07050238 — Evaluation of a Group-based, Skills Training for Increasing Mental Toughness · NA · recruiting
NCT07286955 — Life Skills Training for Soldiers Arriving at Their First Duty Location · NA · recruiting
NCT07121452 — Telehealth for Sleep Apnea: Effectiveness, Implementation, and Cost in the Military Health System · NA · recruiting
NCT07267819 — Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05481177 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Uniformed Services University of the Health Sciences
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05481177.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing